(Q41181294)

27 September 2017

CHK it out! Blocking WEE kinase routs TP53 mutant cancer (English)

1 reference

27 September 2017

Julie E Bauman

1

1 reference

PMCID

4860818

27 September 2017

Christine H Chung

series ordinal

2

1 reference

PMCID

4860818

27 September 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

27 September 2017

Clinical Cancer Research

1 reference

27 September 2017

20

1 reference

27 September 2017

16

1 reference

27 September 2017

4173-4175

1 reference

Functional kinomics identifies candidate therapeutic targets in head and neck cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

28 September 2017

p53 mutations in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

The mutational landscape of head and neck squamous cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4860818

10.1158/1078-0432.CCR-14-0720

28 September 2017

Identifiers

DOI

1 reference

27 September 2017

1 reference

27 September 2017

1 reference

PMCID

4860818